Actuarial Outpost
 
Go Back   Actuarial Outpost > Actuarial Discussion Forum > Health - Disability
FlashChat Actuarial Discussion Preliminary Exams CAS/SOA Exams Cyberchat Around the World Suggestions


Reply
 
Thread Tools Display Modes
  #21  
Old 09-23-2015, 11:45 AM
exponentialpi's Avatar
exponentialpi exponentialpi is online now
Member
SOA AAA
 
Join Date: Nov 2008
Location: Po
Studying for ACA
College: Graduate of hard knocks
Favorite beer: Cold Smoke
Posts: 1,307
Default

Quote:
Originally Posted by Loner View Post
Were he the actual creator of the drug and not a secondary buyer of the rights he might have had a shred of a point.
Rumor is he was shorting stock before his announcement. A ploy to make a quick buck.
Reply With Quote
  #22  
Old 09-23-2015, 01:15 PM
lifishing007's Avatar
lifishing007 lifishing007 is offline
Member
SOA
 
Join Date: Feb 2009
Studying for Advanced
Posts: 2,690
Default

Quote:
Originally Posted by exponentialpi View Post
Rumor is he was shorting stock before his announcement. A ploy to make a quick buck.
Can we charge him inside trading?
__________________
Exam: GHCORE GHADV GHSPE
Module: HF FE PRFM DMAC
Reply With Quote
  #23  
Old 09-23-2015, 03:03 PM
mathmajor's Avatar
mathmajor mathmajor is offline
Member
SOA AAA
 
Join Date: Dec 2010
Location: Nowhere in particular
Studying for Japanese
College: B.S. Applied Math
Favorite beer: La Croix Grapefruit
Posts: 8,287
Default

The free market at work
__________________
FSA

Please forgive unintended sarcasm
Reply With Quote
  #24  
Old 09-23-2015, 03:28 PM
JMO's Avatar
JMO JMO is offline
Carol Marler
Non-Actuary
 
Join Date: Sep 2001
Location: Back home again in Indiana
Studying for Nothing actuarial.
Posts: 36,597
Default

Quote:
Originally Posted by lifishing007 View Post
Can we charge him inside trading?
Please?
__________________
Carol Marler, "Just My Opinion"

Pluto is no longer a planet and I am no longer an actuary. Please take my opinions as non-actuarial.


My latest favorite quotes, updated Oct 13, 2017.

Spoiler:
I should keep these four permanently.
Quote:
Originally Posted by rekrap View Post
JMO is right
Quote:
Originally Posted by campbell View Post
I agree with JMO.
Quote:
Originally Posted by Westley View Post
And def agree w/ JMO.
Quote:
Originally Posted by MG View Post
This. And everything else JMO wrote.
And this all purpose permanent quote:
Quote:
Originally Posted by Dr T Non-Fan View Post
Yup, it is always someone else's fault.
MORE:
Quote:
Originally Posted by Bro View Post
I recommend you get perspective.
Quote:
Originally Posted by Enough Exams Already View Post
Dude, you can't fail a personality test. It just isn't that kind of test.
Quote:
Originally Posted by Locrian View Post
I'm disappointed I don't get to do both.
Reply With Quote
  #25  
Old 09-28-2015, 04:30 PM
Guest
Guest
 
Posts: n/a
Default

Biotech shares are getting hammered today.

Clinton came out and publicly said that Shkreli should lower the price of Daraprim all the way back to its pre-acquisition price.

Looks like Pharma is killing the golden goose and might actually be held accountable for outrageous prices. One guy got called out on his bullshit and now the entire industry might finally get what is coming.
Reply With Quote
  #26  
Old 09-28-2015, 04:41 PM
YetAnotherCareerChanger's Avatar
YetAnotherCareerChanger YetAnotherCareerChanger is offline
Member
CAS
 
Join Date: Jan 2014
Posts: 2,386
Default

Quote:
Originally Posted by Dismal Science View Post
Biotech shares are getting hammered today.

Clinton came out and publicly said that Shkreli should lower the price of Daraprim all the way back to its pre-acquisition price.

Looks like Pharma is killing the golden goose and might actually be held accountable for outrageous prices. One guy got called out on his bullshit and now the entire industry might finally get what is coming.
If it happens :
Reply With Quote
  #27  
Old 09-28-2015, 04:45 PM
Guest
Guest
 
Posts: n/a
Default

Valeant Plummets After Democrats Seek Subpoena on Drug Price Hikes

Quote:
Originally Posted by Bloomberg
Valeant Pharmaceuticals International Inc. shares fell as much as 20 percent after Democrats in the U.S. House asked to subpoena the company for documents relating to drug price increases, the latest move by politicians seeking to curb price hikes on acquired drugs.

“We believe it is critical to hold drug companies to account" when they buy old drugs and raise their prices, 18 Democratic representatives wrote in a letter to Jason Chaffetz, the chairman of the House’s committee on oversight and government reform. They highlighted Valeant’s heart drugs Nitropress and Isuprel, whose prices increased by 212 percent and 525 percent the day that Valeant acquired the rights to sell them.

Valeant’s shares have fallen for three straight days after Democratic presidential candidate Hillary Clinton said last week that she would reform the drug industry to protect consumers from price hikes. Clinton was responding to media reports on Turing Pharmaceuticals AG Chief Executive Officer Martin Shkreli, a former hedge fund manager who raised the price of a decades-old antibiotic 50-fold, to $750 a pill from $13.50 a pill, after acquiring it.

Clinton outlined a plan that included a mandate on research and development spending, a proposal which could hurt companies like Valeant that rely on serial acquisitions to build a pipeline of drug candidates. Last year, Valeant spent $246 million on R&D, far less than companies of similar size, according to data compiled by Bloomberg.

“Valeant is using precisely the same business model as Martin Shkreli," the Democrats said in their letter to Chaffetz Monday. “Both appear to be engaging in the same business model of acquiring potentially life-saving drugs to maximize their own corporate profits."

Laurie Little, a spokeswoman for Valeant, didn’t immediately respond to a call and e-mail seeking comment. Mike Pearson, Valeant’s CEO, told employees Monday that the drug company’s business model doesn’t rely on large price increases and that increased pressure from politicians to curb government reimbursements won’t hurt the company.

“Valeant is well positioned for strong organic growth, even assuming little to no price increases," Pearson said in a letter to employees on Monday before the Democrats made their letter public. Reimbursements from U.S. government programs represent 15 percent of Valeant’s revenue, “lower than any other major pharmaceutical company," he said.
Take them all down, imo
Reply With Quote
  #28  
Old 09-28-2015, 04:45 PM
YetAnotherCareerChanger's Avatar
YetAnotherCareerChanger YetAnotherCareerChanger is offline
Member
CAS
 
Join Date: Jan 2014
Posts: 2,386
Default

Also I thought this article was interesting and relevant.

WBUR Boston (NPR)

Cancer Drug Mark-Ups: Year Of Gleevec Costs $159 To Make But Sells For $106K
Quote:
Originally Posted by The Article
The rocketing cost of prescription drugs garners almost daily attention lately. Polls say it’s high on the list of Americans’ health care worries; presidential candidates are calling for sweeping reform; a storm erupts when one company jacks up the price of an HIV drug by 5,000 percent.

And now, research reveals the yawning gap between the price of widely used cancer drugs and their actual cost.

The true cost — what drug makers have to spend to get those pills to your local pharmacy — is made up of the active ingredient and other chemicals, their formulation into a pill, packaging, shipping and a profit margin.

British researchers, in a report to be delivered this weekend at a European cancer conference, say the price of five common cancer drugs is more than 600 times higher than they cost to make.

For instance, the analysis figures the true cost of a year’s supply of Gleevec (generic name imatinib), used to treat certain kinds of leukemia, at $159.

But the yearly price tag for Gleevec is $106,322 in the U.S. and $31,867 in the U.K. A generic version costs about $8,000 in Brazil.

“We were quite surprised just how cheap a lot of these cancer drugs really are,” pharmacologist Andrew Hill of the University of Liverpool said in an interview. “There’s a lot of scope for prices to come down.”

Hill’s team got the ingredient costs from a public data base called IndiaInfoDrive.com. The Liverpool group did the same analysis for four other drugs in the same class, called tyrosine kinase inhibitors, or TKIs. They’re used to treat lung, breast, liver, pancreas and thyroid cancer as well as leukemias. Their names are Tarceva (erlotinib), Nexavar (sorafenib), Tykerb (lapatinib) and Sprycel (dasatinib).

The true yearly cost of these four drugs ranges from $236 for Tarceva to $4,022 for Tykerb. But their U.S. sticker prices range from $78,797 to $135,679.

The analysis has implications beyond the United States. Hill says more than a million cancer patients around the world meet criteria for taking the five TKI pills. “Very few of them are being treated now,” he says, because the drugs are so expensive.

Cont at ...
Reply With Quote
  #29  
Old 09-28-2015, 04:48 PM
lifishing007's Avatar
lifishing007 lifishing007 is offline
Member
SOA
 
Join Date: Feb 2009
Studying for Advanced
Posts: 2,690
Default

Quote:
Originally Posted by JMO View Post
Please?
It's only a matter of want, not need.
__________________
Exam: GHCORE GHADV GHSPE
Module: HF FE PRFM DMAC
Reply With Quote
  #30  
Old 09-28-2015, 05:19 PM
FormLetter's Avatar
FormLetter FormLetter is offline
Member
 
Join Date: Feb 2006
Posts: 48,521
Default

In clinical situations it is hard to separate want from need.
__________________
Come join the AO Rap Battle Tournament 2013:
http://www.actuarialoutpost.com/actu...33#post7082433
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


All times are GMT -4. The time now is 03:13 PM.


Powered by vBulletin®
Copyright ©2000 - 2018, Jelsoft Enterprises Ltd.
*PLEASE NOTE: Posts are not checked for accuracy, and do not
represent the views of the Actuarial Outpost or its sponsors.
Page generated in 0.15755 seconds with 9 queries